TABLE 3.
Incidence, clinical characteristics and viral kinetics parameters of CMV events.
| Asymptomatic CMV infection | |
|---|---|
| Number of patients with at least one episode | 114 |
| Cumulative incidence, % (95% CI) | 39.2 (33.5–45.0) |
| Interval from transplantation to the first episode, days [median (IQR)] | 71.0 (35.8–149.3) |
| Late-onset infection (beyond day 180), n (%) a | 53/269 (19.7) |
| Requirement for pre-emptive therapy, n (%) | 39/114 (34.2) |
| Patients with recurrent infection, n (%) b | 27 (23.7) |
| Number of episodes of viremia | 166 |
| Peak viral load, log10 IU/ml [median (IQR)] | 3.2 (2.7–3.8) |
| Episodes requiring antiviral therapy | 42/166 (25.3) |
| Viral load, log10 IU/ml [median (IQR)] | 3.5 (3.2–3.9) |
| Episodes not requiring antiviral therapy | 124/166 (74.7) |
| Viral load, log10 IU/ml [median (IQR)] | 2.9 (2.5–3.6) |
| CMV-AUC0-360, log10 IU × days × ml−1 [median (IQR)] | 4.7 (4.1–5.2) |
| CMV disease | |
| Number of patients with at least one episode | 32 |
| Cumulative incidence, % (95% CI) | 11.0 (7.4–14.6) |
| Interval from transplantation to the first episode, days [median (IQR)] | 50.0 (34.0–176.5) |
| Clinical syndrome [n (%)] | |
| Viral syndrome | 27/32 (84.4) |
| Colitis | 4/32 (12.5) |
| Hepatitis | 1/32 (3.1) |
CI: interval confidence; CMV: cytomegalovirus; CMV-AUC: area under curve of CMV viral load; IQR: interquartile range.
a
Percentage calculated on the basis of those KT, recipients that remained alive with a functioning graft by day 180 after transplantation (n = 269).
b
At least two episodes separated by both a minimum 2-weeks interval and at least one negative sample for CMV DNA.